arrow
C

Chelsea McLean

Johnson & Johnson
H指数:15
被引数:1,789

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Leroux-Roels et al. Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. Vaccines 2026, 14, 146

更正:Leroux-Roels 等人。ExPEC9V 大肠杆菌疫苗与高剂量流感疫苗联合接种在老年人中的免疫原性和安全性:一项安慰剂对照、随机、III 期研究。Vaccines 2026, 14, 146

2026-08-050
OAAI
A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study

一种1组血凝素茎疫苗在1/2a期研究中诱导针对流感的广泛体液免疫反应

2026-04-130
OAAI
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

刚果民主共和国成人和儿童Ad26.ZEBOV,mva-bn-filo埃博拉疫苗方案延长剂量间隔的免疫原性

2024-07-230
OAAI
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
2024-07-015
PRE
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without Human Immunodeficiency Virus in Africa

在非洲有和没有人类免疫缺陷病毒的成年人中加速异源2剂量埃博拉疫苗方案的安全性和免疫原性

2024-04-241
PRE
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Ad26.ZEBOV,mva-bn-filo埃博拉病毒疫苗方案的批次一致性,免疫原性和安全性: 一项3期,随机,双盲,安慰剂对照试验

2024-03-241
OAAI
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active- controlled trial in Guinea and Sierra Leone
2023-11-015
OAAI
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

免疫记忆的持久性是长期疫苗诱导的人类埃博拉病毒疾病保护的潜在关联

2023-09-017
OAAI
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo

刚果民主共和国医疗保健提供者和前线的异源2剂量Ad26.ZEBOV,mva-bn-filo疫苗方案的安全性和免疫原性

2023-08-242
OAAI
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
2023-05-011
OAAI
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
2023-03-0112
OAAI
Randomized Trial of Vaccines for Zaire Ebola Virus Disease
2022-12-2940
OA
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

基于类器官药物反应的结直肠癌患者前瞻性实验治疗

2021-06-0185
OAAI